progressive supranuclear palsy
Conditions
Interventions
Gold Standard:Diagnostic criteria of MDS for progressive supra-nuclear palsy (2017) and the Chinese clinical diagnostic criteria for progressive supra-nuclear palsy (2016).
Index test:The 
of 
PSP 
scales. 
protein-related 
examination 
(for 
example, 
protein 
in 
Sponsors
Huashan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
40 Years to 85 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria for patients with progressive supranuclear palsy: The primary basic diagnostic criterion is the clinical diagnosis of progressive supranuclear palsy. Subject: A patient with clinical diagnosis of progressive supranuclear palsy. Specific inclusion criteria: 1. Citizens of the People's Republic of China, male or female, between the ages of 40 and 85. 2. The patient was clinically diagnosed as progressive supranuclear palsy at the first visit; It meets the diagnostic criteria of MDS for progressive supra-nuclear palsy (2017) and the Chinese clinical diagnostic criteria for progressive supra-nuclear palsy (2016), and is independently diagnosed as "clinically proposed progressive supra-nuclear palsy" by two motion disorder specialists in the Department of Neurology of Huashan Hospital. Patients with controversial diagnosis shall be decided by the professional group of motor disorders in the Department of Neurology of Huashan Hospital through collective discussion. However, Tau protein related pathological examination recommended by necessary diagnostic criteria should be carried out in the subsequent research process, and necessary diagnostic confirmation or diagnostic changes should be made. 3. Symptoms and severity of disease Subjects recruited for this study were required to have the basic diagnostic characteristics of progressive supranuclear palsy. The specific symptom spectrum refers to the diagnostic criteria for eye movement disorder, balance disorder, sedentary symptoms, cognitive and language impairment, etc. At the first visit, the patient was able to walk independently with the aid of external objects (HY grading less than or equal to 4). 4. Fully understand and sign the informed consent for this study.
Exclusion criteria
Exclusion criteria: 1. Obvious mental symptoms or severe depression. 2. Patients with significant cognitive impairment (MMSE < 20 points). 3. Severe loss of postural reflexes (inability to stand and walk independently). 4. Feeding through a nasal feeding tube. 5. Women of childbearing age who were pregnant at the time of enrollment. 6. Have a definite history of brain disease (a definite history of stroke, traumatic brain injury, brain tumor, hydrocephalus) 7. Patients with serious medical diseases such as heart, liver and kidney. 8. The researcher believes that he is not suitable to participate in other situations in this study. 9. Participants in other clinical trials in the same period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PSP rating scales; | — |
Secondary
| Measure | Time frame |
|---|---|
| Tau levels in blood/CSF;Tau levels in the brain; | — |
Countries
China
Contacts
Public ContactJian Wang
Huashan Hospital, Fudan University
Outcome results
None listed